お知らせ • Jun 18
Silver Phoenix Resources Inc., Annual General Meeting, Jul 28, 2022 Silver Phoenix Resources Inc., Annual General Meeting, Jul 28, 2022. お知らせ • Apr 13
Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. entered into a binding memorandum of understanding to acquire Silver Phoenix Resources Inc. (CNSX:SP) for approximately CAD 190 million in a reverse merger transaction. Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. entered into a binding memorandum of understanding to acquire Silver Phoenix Resources Inc. (CNSX:SP) (SPR) for approximately CAD 190 million in a reverse merger transaction on April 8, 2022. As a part of transaction, the shareholders of Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. will be issued common shares of Silver Phoenix Resources Inc. with an aggregate deemed value of CAD 189 million. The MOU also provides that effective on closing of the Proposed Transaction SPR will, among other things: (i) change its name to a name requested by Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. and acceptable to applicable regulatory authorities; (ii) increase the size of its board of directors to between five and nine and (ii) replace all directors and officers of the Company on closing of the Proposed Transaction with nominees of Atlas Biotechnologies Inc. & AgMedica Bioscience Inc. & Cambrosia Ltd. On completion of the Proposed Transaction, SPR's Board of Directors and management team will be reconstituted to include Sheldon Croome, Chief Executive Officer; Jeffrey R. Gossain, President and Kevin Mills, Chief Financial Officer.
Completion of the Proposed Transaction is subject to a number of conditions, including receipt of all necessary shareholder and regulatory approvals, execution of related transaction documents, approval of the Exchange, disposition of SPR's mining assets, there being no adverse material change in the affairs of the parties and completion of satisfactory due diligence by each of the parties. The MOU shall terminate upon any party notifying the others that it is not satisfied with the results of its due diligence investigation by April 30, 2022. Closing of the Proposed Transaction will take place in the second or third quarter of 2022 and in any event prior to October 31, 2022. Kronos Capital Partners acted as financial advisor to Agmedica Bioscience Inc. with respect to the Proposed Transaction. Board Change • Mar 05
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Feb 11
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. President, CEO, Corporate Secretary & Director Scott Ackerman was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.